
Advanced Accelerator Applications SA
- Home
- Companies & Suppliers
- Advanced Accelerator Applications SA
- Downloads
- PLUVICTO - Brochure
PLUVICTO - Brochure
PLUVICTO is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Most popular related searches
Stay in the loop!
Select your areas of interest to receive industry updates.